Dihydrotestosterone and Free/Total Prostatic Specific Antigen Ratio in Diagnosis and Prognosis of Prostatic Disease

Prostate cancer (PCa) is the most commonly diagnosed male malignancy after 60 years old. Today, the problem is to distinguish between low-risk and agrressive cancers, especially in patients with Prostatic Specific Antigen (PSA) less than 10 ng/ml The use of PSA as a biomarkers for diagnosis and prognosis of prostate cancer has the potential to improve the clinical management of the patients. PSA levels. together with clinical examination, prostate ultrasound and histopatological examination are esential for the diagnostic of PCa, risk assessment and therapeutic decisions. The aim of our study is to evaluate the patients with PSA values less then 10 ng/mL and to determine the correct indications for tratment depending on the risk scale of the disease. The inclusion criteria for the patients are described in the paper. For improving the early diagnosis of PCa in patients with PSA below 10 ng/mL we developed an algoritm based on current opportunities.

Download Full-text

1263: Preoperative Prostatic Specific Antigen is Correlated with Tumor Volume and Prostate Weight and Predictive of Biochemical Recurrence

The Journal of Urology ◽

10.1016/s0022-5347(18)38488-x ◽

2004 ◽

Vol 171 (4S) ◽

pp. 332-333

Author(s):

Paula J. Bunde ◽

Michael O. Koch ◽

Richard Bihrle ◽

Thomas A. Gardner ◽

John N. Eble ◽

...

Keyword(s):

Biochemical Recurrence ◽

Tumor Volume ◽

Specific Antigen ◽

Prostatic Specific Antigen ◽

Prostate Weight

Download Full-text

Prostatic specific antigen (PSA) estimations during radiation therapy: A prognostic indicator?

Clinical Oncology ◽

10.1016/s0936-6555(05)81253-1 ◽

1991 ◽

Vol 3 ◽

pp. 298-298

Keyword(s):

Radiation Therapy ◽

Specific Antigen ◽

Prognostic Indicator ◽

Prostatic Specific Antigen

Download Full-text

Body Mass Index and prostatic-specific antigen are predictors of prostate cancer metastases in patients undergoing robot-assisted radical prostatectomy and extended pelvic lymph node dissection

Minerva Urologica e Nefrologica ◽

10.23736/s0393-2249.19.03401-5 ◽

2019 ◽

Vol 71 (5) ◽

Cited By ~ 5

Author(s):

Antonio B. Porcaro ◽

Alessandro Tafuri ◽

Marco Sebben ◽

Tania Processali ◽

Marco Pirozzi ◽

...

Keyword(s):

Prostate Cancer ◽

Body Mass Index ◽

Lymph Node ◽

Radical Prostatectomy ◽

Specific Antigen ◽

Pelvic Lymph Node Dissection ◽

Prostatic Specific Antigen ◽

Node Dissection ◽

Robot Assisted ◽

Cancer Metastases

Download Full-text

The Role of Chromogranin A (CgA) in Monitoring Patients with Prostate Cancer Under Androgen Deprivation Therapy: Comparison with Prostatic Specific Antigen (PSA)

Current Radiopharmaceuticals ◽

10.2174/1874471010801020115 ◽

2008 ◽

Vol 1 (2) ◽

pp. 115-119

Author(s):

Athanasios Bantis ◽

Petros Sountoulides ◽

Athanasios Zissimopoulos ◽

Christos Kalaitzis ◽

Stilianos Giannakopoulos ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Deprivation Therapy ◽

Chromogranin A ◽

Specific Antigen ◽

Androgen Deprivation ◽

Prostatic Specific Antigen

Download Full-text

The electrochemical immunosensor for detection of prostatic specific antigen using quince seed mucilage-GNPs-SNPs as a green composite

Bioelectrochemistry ◽

10.1016/j.bioelechem.2021.107744 ◽

2021 ◽

Vol 139 ◽

pp. 107744

Author(s):

Elahe Darvishi ◽

Hosna Ehzari ◽

Mohsen Shahlaei ◽

Leila Behbood ◽

Elham Arkan

Keyword(s):

Specific Antigen ◽

Electrochemical Immunosensor ◽

Prostatic Specific Antigen ◽

Green Composite ◽

Seed Mucilage

Download Full-text

Prostate Cancer Liquid Biopsy Biomarkers’ Clinical Utility in Diagnosis and Prognosis

Cancers ◽

10.3390/cancers13133373 ◽

2021 ◽

Vol 13 (13) ◽

pp. 3373

Author(s):

Milena Matuszczak ◽

Jack A. Schalken ◽

Maciej Salagierski

Keyword(s):

Prostate Cancer ◽

Liquid Biopsy ◽

Current Knowledge ◽

Prostate Gland ◽

Specific Antigen ◽

Transrectal Ultrasound ◽

Digital Rectal Examination ◽

Cost Effective ◽

Non Invasive ◽

Diagnosis And Prognosis

Prostate cancer (PCa) is the most common cancer in men worldwide. The current gold standard for diagnosing PCa relies on a transrectal ultrasound-guided systematic core needle biopsy indicated after detection changes in a digital rectal examination (DRE) and elevated prostate-specific antigen (PSA) level in the blood serum. PSA is a marker produced by prostate cells, not just cancer cells. Therefore, an elevated PSA level may be associated with other symptoms such as benign prostatic hyperplasia or inflammation of the prostate gland. Due to this marker’s low specificity, a common problem is overdiagnosis, which leads to unnecessary biopsies and overtreatment. This is associated with various treatment complications (such as bleeding or infection) and generates unnecessary costs. Therefore, there is no doubt that the improvement of the current procedure by applying effective, sensitive and specific markers is an urgent need. Several non-invasive, cost-effective, high-accuracy liquid biopsy diagnostic biomarkers such as Progensa PCA3, MyProstateScore ExoDx, SelectMDx, PHI, 4K, Stockholm3 and ConfirmMDx have been developed in recent years. This article compares current knowledge about them and their potential application in clinical practice.

Download Full-text

Concentrations of canine prostate specific esterase, CPSE, at baseline are associated with the relative size of the prostate at three-year follow-up

BMC Veterinary Research ◽

10.1186/s12917-021-02874-1 ◽

2021 ◽

Vol 17 (1) ◽

Author(s):

Bodil S. Holst ◽

Sofia Carlin ◽

Virginie Fouriez-Lablée ◽

Sofia Hanås ◽

Sofie Ödling ◽

...

Keyword(s):

Clinical Symptoms ◽

Specific Antigen ◽

Relative Size ◽

Clinical Signs ◽

Serum Concentrations ◽

Prostatic Disease ◽

Follow Up Study ◽

Prostate Size ◽

Prostate Growth

Abstract Background Enlargement of the prostate is associated with prostatic diseases in dogs, and an estimation of prostatic size is a central part in the diagnostic workup. Ultrasonography is often the method of choice, but biomarkers constitute an alternative. Canine prostate specific esterase (CPSE) shares many characteristics with human prostate specific antigen (PSA) and is related to prostate size. In men with clinical symptoms of prostatic disease, PSA concentrations are related to prostate growth. The aims of the present follow-up study were to evaluate if the concentration of CPSE is associated with future growth of the prostate, and if analysis of a panel of 16 steroids gives further information on prostatic growth. Owners of dogs included in a previous study were 3 years later contacted for a follow-up study that included an interview and a clinical examination. The prostate was examined by ultrasonography. Serum concentrations of CPSE were measured, as was a panel of steroids. Results Of the 79 dogs included at baseline, owners of 77 dogs (97%) were reached for an interview, and 22 were available for a follow-up examination. Six of the 79 dogs had clinical signs of prostatic disease at baseline, and eight of the remaining 73 dogs (11%) developed clinical signs between baseline and follow-up, information was lacking for two dogs. Development of clinical signs was significantly more common in dogs with a relative prostate size of ≥2.5 at baseline (n = 20) than in dogs with smaller prostates (n = 51). Serum concentrations of CPSE at baseline were not associated with the change in prostatic size between baseline and follow-up. Serum concentrations of CPSE at baseline and at follow-up were positively associated with the relative prostatic size (Srel) at follow-up. Concentrations of corticosterone (P = 0.024), and the class corticosteroids (P = 0.0035) were positively associated with the difference in Srel between baseline and follow-up. Conclusions The results support the use of CPSE for estimating present and future prostatic size in dogs ≥4 years, and the clinical usefulness of prostatic size for predicting development of clinical signs of prostatic disease in the dog. The association between corticosteroids and prostate growth warrants further investigation.

Download Full-text